Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine

BIOLOGICAL10 trials

Sponsors

Sanofi Pasteur, a Sanofi Company

Conditions

Healthy VolunteersHealthy Volunteers (Meningococcal Infection)MeningitisMeningococcal ImmunisationMeningococcal Immunisation (Healthy Volunteers)Meningococcal InfectionMeningococcal Infection (Healthy Volunteers)Meningococcal Infections

Phase 2

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers

CompletedNCT03205358

Sanofi Pasteur, a Sanofi CompanyMeningitis, Meningococcal Infections, Meningococcal Meningitis

Start: 2015-03-31End: 2015-08-19Updated: 2022-04-04

Phase 3

Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

CompletedNCT02752906

Sanofi Pasteur, a Sanofi CompanyMeningitis, Meningococcal Infections, Meningococcal Meningitis

Start: 2016-04-15End: 2016-12-19Updated: 2022-04-05

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older

CompletedNCT02842866

Sanofi Pasteur, a Sanofi CompanyMeningitis, Meningococcal Infections, Meningococcal Meningitis

Start: 2016-07-15End: 2017-02-13Updated: 2022-04-05

Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

CompletedNCT02842853

Sanofi Pasteur, a Sanofi CompanyMeningitis, Meningococcal Infections, Meningococcal Meningitis

Start: 2016-07-15End: 2017-02-28Updated: 2022-04-05

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers

CompletedNCT02955797

Sanofi Pasteur, a Sanofi CompanyMeningitis, Meningococcal Infections, Meningococcal Meningitis

Start: 2017-02-24End: 2017-10-26Updated: 2022-04-05

Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico

CompletedNCT03630705

Sanofi Pasteur, a Sanofi CompanyHealthy Volunteers (Meningococcal Infection)

Start: 2018-10-17End: 2022-02-18Updated: 2023-10-19

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers

CompletedNCT03890367

Sanofi Pasteur, a Sanofi CompanyMeningococcal Immunisation (Healthy Volunteers)

Start: 2019-09-12End: 2020-10-14Updated: 2025-09-15

Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49

CompletedNCT04142242

Sanofi Pasteur, a Sanofi CompanyMeningococcal Infection (Healthy Volunteers)

Start: 2019-10-04End: 2022-05-25Updated: 2025-09-11

Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa

CompletedNCT05794230

Sanofi Pasteur, a Sanofi CompanyHealthy Volunteers, Meningococcal Immunisation

Start: 2023-03-27End: 2025-11-15Updated: 2026-01-21

Unknown Phase

Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)

RecruitingNCT04843111

Sanofi Pasteur, a Sanofi CompanyMeningococcal Infection

Start: 2021-03-05End: 2028-05-18Target: 50Updated: 2025-12-01

Related Papers

Safety and immunogenicity of a 3-dose schedule of a quadrivalent meningococcal tetanus toxoid conjugate vaccine administered concomitantly with routine pediatric vaccines to infants and toddlers: A descriptive randomized study

2026-01-01

Safety and immunogenicity of a 3-dose schedule of a quadrivalent meningococcal tetanus toxoid conjugate vaccine administered concomitantly with routine pediatric vaccines to infants and toddlers: A descriptive randomized study

2026-01-01

Safety and immunogenicity of a 3-dose schedule of a quadrivalent meningococcal tetanus toxoid conjugate vaccine administered concomitantly with routine pediatric vaccines to infants and toddlers: A descriptive randomized study.

2025-12-01

Five-Year Immune Persistence of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) and Immunogenicity and Safety of a Booster Dose in Children

Infectious Diseases and Therapy2025-04-017 citations

Immune persistence and booster response of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) 5 years after primary vaccination of adults at ≥56 years of age

Human Vaccines & Immunotherapeutics2024-11-183 citations

1157. Immune Persistence and Booster Response of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) 5 Years After Primary Vaccination of Adults ≥59 Years of Age

Open Forum Infectious Diseases2023-11-27

Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study

Pediatric Research2023-03-1011 citations

Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged ≥59 years: A phase III randomized study

Human Vaccines & Immunotherapeutics2023-01-0211 citations

Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial

Human Vaccines & Immunotherapeutics2022-04-218 citations

1046. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered as a Booster to Adults ≥ 59 Years of Age

Open Forum Infectious Diseases2021-11-011 citations

Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study

Human Vaccines & Immunotherapeutics2021-06-0416 citations

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT)<i>vs</i>. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-naïve and meningococcal C conjugate vaccine-primed toddlers: a phase III randomised study

Epidemiology and Infection2021-01-0120 citations

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a phase III randomised study

Epidemiology and Infection2021-01-0114 citations

Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: A Phase III randomized study.

2020-06-1925 citations

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in ≥56-year-olds: A Phase III randomized study.

2020-05-0621 citations

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study

Human Vaccines & Immunotherapeutics2020-04-0136 citations

Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study

Human Vaccines & Immunotherapeutics2020-03-2530 citations

2723. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Adolescents 10–17 Years of Age

Open Forum Infectious Diseases2019-10-013 citations

2719. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Adults 18–55 Years of Age

Open Forum Infectious Diseases2019-10-012 citations

2725. Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Adolescents and Adults

Open Forum Infectious Diseases2019-10-011 citations

1 more papers not shown